Combining Asciminib with Ponatinib Suppresses Emergence Highly Resistant BCR-ABL1 Mutants

We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines. Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compound mutants at clinically achievable concentrations. Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.

https://www.sciencedirect.com/science/article/abs/pii/S1535610819303721?via%%203Dihub